Matthew A. Taylor

Pharmacology, Toxicology and PharmaceuticsMedicineEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)”.

Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)

EClinicalMedicine(2020)10.1016/j.eclinm.2020.100693

N/A

0.312DataRank · unranked

7 citations

Shamia Hoque, Nancy F. Olivieri, Matthew A. Taylor, David M. Aboulafia, Courtney Lubaczewski +29 more

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions

The Lancet Oncology(2020)10.1016/s1470-2045(20)30485-x

N/A

0DataRank · unranked

30 citations

Martin W. Schoen, Shamia Hoque, Bartlett J. Witherspoon, David M. Aboulafia, Catherine S. Hwang +9 more